Omeros Corporation to Host Third Quarter 2009 Financial Results Conference Call on November 19
SEATTLE, WA, Nov 13, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Omeros Corporation (Nasdaq: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system, today announced that it will hold a conference call on Thursday, November 19, 2009 to discuss the Company's third quarter 2009 results and provide a corporate update. Gregory A. Demopulos, M.D., Chairman and CEO of Omeros, will host the call beginning at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time). A press release for the third quarter ended September 30, 2009 will be released after markets close on November 19.
To access the live call by telephone, please dial 877-795-3638 (United States) or 719-325-4891 (International). In addition, the live conference call is being webcast and can be accessed on the "Events" page of the Company's website at http://www.omeros.com.
A replay of the webcast will be available on the Company's website for one week. A telephone replay will be available starting at 7:00 p.m. Eastern Time on November 19 until 11:59 p.m. Eastern Time on November 22, which can be accessed by dialing 888-203-1112 (United States) or 719-457-0820 (International) and entering conference ID number 4396920.
About Omeros Corporation
Omeros Corporation is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. Omeros' most clinically advanced product candidates are derived from its proprietary PharmacoSurgery(TM) platform designed to improve clinical outcomes of patients undergoing arthroscopic, ophthalmological, urological and other surgical and medical procedures. Omeros has four ongoing PharmacoSurgery(TM) clinical development programs, and its lead product candidate, OMS103HP, is being evaluated in Phase 3 clinical trials for use during arthroscopic surgery to improve postoperative joint function and reduce postoperative pain. Omeros is also building a diverse pipeline of preclinical programs targeting inflammation and central nervous system disorders.
SOURCE Omeros Corporation
Copyright (C) 2009 PR Newswire. All rights reserved